Lorella Garofalo is the Head of Regulatory Affairs at Pfizer Canada, a role she took in 2014 after having served the company since 2001 assuming roles of increasing responsibility in clinical research as well as medical affairs. She obtained a BSc (Honours) in Biochemistry and a PhD in Pharmacology & Therapeutics from McGill University. Prior to joining Pfizer, Lorella was a drug assessment officer at TPD, Health Canada and since 1999 has maintained an academic appointment with the department of Pharmacology & Therapeutics at McGill. She has served as a member of the board of directors/advisory councils for various research organizations and is a member of the regulatory affairs committees of Innovative Medicines Canada and BIOTECanada.
Day 1: Oct 6, 2020
Streamlining the Path to Market: Regulatory Modernization – Is Canada a Land of Regulatory Obstacles or Opportunities?
The federal government has faced challenges in updating regulations to keep up with the modern changes to drug discovery and with market access. The result could be viewed as an onerous regulatory burden or as regulatory clarity paving the way for future opportunities. Take back to your team actionable insights about:
- The benefits expected from the current federal regulatory modernization project
- Whether perceived regulatory burdens can be alleviated or reduced
- How greater clarity in updated regulations can translate into opportunities for market access
Learn how to reduce regulatory burden and leverage regulatory modernization into increased opportunities
Day 2: Oct 7, 2020
Day 3: Oct 8, 2020